Jun 27, 2023 · Next generation off-the-shelf, optimally engineered natural killer cell therapies targeting hematological malignancies and solid tumors. Our unique optimally engineered approach leverages an innovative proprietary platform to optimize the function of natural killer cells, thus maximizing cancer cell killing.

We are advancing a growing portfolio of off-the-shelf, optimally engineered NK cell therapy candidates that express not only a specific tumor antigen targeted CAR, but also have undergone different gene edits (e.g. CISH KO, CD38 KO and TGF β R2 KO) and additional construct features including a TNF-related apoptosis-inducing ligand variant (TRAIL...

Jan 6, 2022 · Galway, Ireland and San Diego, USA, 06 January 2022 – ONK Therapeutics, an innovative NK cell therapy platform company, today announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management.

ONK is set to bring the natural benefits of NK cells over T cells to bear on MUC-1, in a tumor-specific fashion, while also further boosting efficacy and countering resistance through its use of...

Dec 6, 2023 · ONK and NAYA plan to assess several combination therapies in preclinical cancer models in 2024 prior to subsequently exploring initiating clinical trials.

May 6, 2020 · ONK is developing novel, off the shelf, NK cell-based therapies for cancer, as well as working to genetically modify NK cells to create a platform which can be tailored for multiple cancers.

Patent • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor.

ACE1702 is manufactured with a proprietary low-cost method using oNK immortalized cell source with stable high expression of multiple NK activation receptors, including CD16, conjugated to anti-HER2 IgG via ACC, and low levels of inhibitory receptors.

Dec 17, 2020 · ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has secured three new exclusive option license agreements which strengthen its off-the-shelf, dual-targeted natural killer (NK) cell therapy platform and extend its pre-clinical pipeline to four programs across both hematological and solid tumors.

Feb 15, 2022 · Intellia grants ONK non-exclusive rights to its ex vivogenome editing and LNP delivery technologies and exclusive rights to certain guide RNAs for up to five allogeneic CRISPR-edited NK cell...